<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03769753</url>
  </required_header>
  <id_info>
    <org_study_id>18-489</org_study_id>
    <nct_id>NCT03769753</nct_id>
  </id_info>
  <brief_title>Trial of IRE in Cholangiocarcinoma</brief_title>
  <official_title>Trial Of IRE in Cholangiocarcinoma (TOnIC): Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test any good and bad side effects of surgery using IRE to&#xD;
      treat cancer of the bile duct.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Actual">August 16, 2021</completion_date>
  <primary_completion_date type="Actual">August 16, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a prospective, single-center phase I study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients experiencing a clinically relevant complications</measure>
    <time_frame>within 30 days post-IRE</time_frame>
    <description>defined as CTCAE (version 5.0) grade 3 or higher complications</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>intraoperative use of IRE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with intraoperatively determined advanced unresectable PHC will be treated with IRE during the same surgical exploration session (N=20). Electrodes will be placed using ultrasound guidance. All electrodes will be placed by hepatopancreatobiliary surgeons with experience using IRE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IRE Device</intervention_name>
    <description>For use in ablating soft tissue</description>
    <arm_group_label>intraoperative use of IRE</arm_group_label>
    <other_name>The NanoKnife IRE device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Capable of providing written and oral informed consent in English&#xD;
&#xD;
          -  Locally advanced disease based on preoperative work-up demonstrating that the tumor is&#xD;
             unresectable due to portal vein, hepatic artery, and/or bile duct involvement,&#xD;
             insufficient hypertrophy response of the future liver remnant after portal vein&#xD;
             embolization, or patients not able to tolerate major liver surgery&#xD;
&#xD;
          -  Found to be unresectable intraoperatively based on vascular, biliary, or lymph node&#xD;
             (N2) involvement upon exploratory laparotomy&#xD;
&#xD;
          -  Patients will be assessed for chemotherapy prior to treatment with IRE, but given the&#xD;
             common problem of recurrent cholangitis, some patients will not be candidates for&#xD;
             chemotherapy until after IRE is performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Locally advanced PHC eligible and accepted for liver transplantation evaluation&#xD;
&#xD;
          -  PHC with &gt; 5 cm extension along the common hepatic duct or common bile duct on&#xD;
             preoperative imaging or intraoperative ultrasound&#xD;
&#xD;
          -  Metastases to peritoneum, liver or other organs confirmed by percutaneous biopsy,&#xD;
             staging laparoscopy or intraoperative frozen section&#xD;
&#xD;
          -  Lymph node metastases beyond N2 stations, confirmed by intraoperative frozen sections&#xD;
             or radiographic diagnosis&#xD;
&#xD;
          -  History of cardiac disease:&#xD;
&#xD;
               -  Congestive heart failure (NYHA class &gt;2)&#xD;
&#xD;
               -  Active Coronary Artery Disease (defined as myocardial infarction within 6 months&#xD;
                  prior to screening)&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers&#xD;
                  are permitted)&#xD;
&#xD;
          -  Any implanted stimulation device (defined as implantable cardiac device and a&#xD;
             pacemaker)&#xD;
&#xD;
          -  Uncontrolled hypertension (blood pressure must be â‰¤160/95 mmHg at the time of&#xD;
             screening on a stable antihypertensive regimen)&#xD;
&#xD;
          -  Uncontrolled infections (&gt; grade 2 NCI-CTC, version 3.0)&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Both narrowing (sclerosis) of the main portal vein and a reduced diameter of either&#xD;
             the common hepatic artery, celiac trunk or superior mesenteric artery of &gt;50%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T. Peter Kingham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Consent and Follow up)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Consent and Follow up)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Consent and Follow up)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Consent and Follow up)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Consent and Follow Up)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Consent and Follow-up)</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intraoperative use of IRE</keyword>
  <keyword>18-489</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

